David  Scadden net worth and biography

David Scadden Biography and Net Worth

Dr. Scadden has served as a member of our board of directors since June 2017. Dr. Scadden is the Gerald and Darlene Jordan Professor of Medicine at Harvard University. He founded and directs the Center for Regenerative Medicine at the Massachusetts General Hospital and co-founded and co-directs the Harvard Stem Cell Institute and is chairman and professor of the Harvard University Department of Stem Cell and Regenerative Biology. Dr. Scadden is a hematologist/oncologist and an expert on the medical applications of stem cell biology with a particular emphasis on its use in the settings of cancer and AIDS. He has published over 300 scientific papers and book chapters, and his laboratory has made fundamental contributions in understanding the regulation of stem cell function. Dr. Scadden is the recipient of numerous honors including membership in the National Academy of Medicine, the American Academy of Arts and Sciences and awards from the American Society of Hematology, the Doris Duke Charitable Trust, the Ellison Medical Foundation, the Burroughs Welcome Fund, and the Leukemia and Lymphoma Society. He has served or serves on the board of scientific counselors for the National Cancer Institute, the board of external experts for the National Heart, Lung and Blood Institute, board of directors of the International Society for Stem Cell Research (ISSCR), and is an associate member of the Broad Institute of Harvard and MIT. He serves on multiple editorial and scientific advisory boards, is a scientific founder of Fate Therapeutics and Magenta Therapeutics and serves on the board of directors for Magenta Therapeutics and Editas Medicine.

What is David Scadden's net worth?

The estimated net worth of David Scadden is at least $455,974.35 as of December 11th, 2024. Dr. Scadden owns 15,483 shares of Agios Pharmaceuticals stock worth more than $455,974 as of April 25th. This net worth evaluation does not reflect any other investments that Dr. Scadden may own. Learn More about David Scadden's net worth.

How do I contact David Scadden?

The corporate mailing address for Dr. Scadden and other Agios Pharmaceuticals executives is 88 SIDNEY STREET, CAMBRIDGE MA, 02139. Agios Pharmaceuticals can also be reached via phone at (617) 649-8600 and via email at investors@agios.com. Learn More on David Scadden's contact information.

Has David Scadden been buying or selling shares of Agios Pharmaceuticals?

David Scadden has not been actively trading shares of Agios Pharmaceuticals over the course of the past ninety days. Most recently, David Scadden sold 200 shares of the business's stock in a transaction on Wednesday, December 11th. The shares were sold at an average price of $46.28, for a transaction totalling $9,256.00. Following the completion of the sale, the director now directly owns 15,483 shares of the company's stock, valued at $716,553.24. Learn More on David Scadden's trading history.

Who are Agios Pharmaceuticals' active insiders?

Agios Pharmaceuticals' insider roster includes Carman Alenson (Insider), Jonathan Biller (CFO & Head of Corp. Affairs ), Christopher Bowden (Insider), James Burns (https://www.linkedin.com/in/jackie-fouse-a90b811aa), Jacqualyn Fouse (CEO & Director ), Jacqualyn Fouse (Director), Sarah Gheuens (Chief Medical Officer, Head of R&D), Brian Goff (CEO), Cecilia Jones (CFO), Tsveta Milanova (Chief Commercial Officer), Darrin Miles (Insider), and David Scadden (Director). Learn More on Agios Pharmaceuticals' active insiders.

Are insiders buying or selling shares of Agios Pharmaceuticals?

In the last year, insiders at the biopharmaceutical company sold shares 5 times. They sold a total of 24,134 shares worth more than $892,435.53. The most recent insider tranaction occured on April, 10th when Director Jacqualyn A Fouse sold 7,497 shares worth more than $194,172.30. Insiders at Agios Pharmaceuticals own 4.9% of the company. Learn More about insider trades at Agios Pharmaceuticals.

Information on this page was last updated on 4/10/2025.

David Scadden Insider Trading History at Agios Pharmaceuticals

See Full Table

David Scadden Buying and Selling Activity at Agios Pharmaceuticals

This chart shows David Scadden's buying and selling at Agios Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$5k$0$5kTotal Insider BuyingTotal Insider Selling

Agios Pharmaceuticals Company Overview

Agios Pharmaceuticals logo
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $29.45
Low: $28.70
High: $29.88

50 Day Range

MA: $30.38
Low: $24.53
High: $35.54

2 Week Range

Now: $29.45
Low: $23.42
High: $62.58

Volume

358,865 shs

Average Volume

704,025 shs

Market Capitalization

$1.69 billion

P/E Ratio

2.60

Dividend Yield

N/A

Beta

0.83